Enhanced detection of circulating tumor DNA by fragment size analysis
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works..
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alterations but have rarely considered the biological properties of plasma cell-free DNA (cfDNA). We hypothesized that differences in fragment lengths of circulating DNA could be exploited to enhance sensitivity for detecting the presence of ctDNA and for noninvasive genomic analysis of cancer. We surveyed ctDNA fragment sizes in 344 plasma samples from 200 patients with cancer using low-pass whole-genome sequencing (0.4×). To establish the size distribution of mutant ctDNA, tumor-guided personalized deep sequencing was performed in 19 patients. We detected enrichment of ctDNA in fragment sizes between 90 and 150 bp and developed methods for in vitro and in silico size selection of these fragments. Selecting fragments between 90 and 150 bp improved detection of tumor DNA, with more than twofold median enrichment in >95% of cases and more than fourfold enrichment in >10% of cases. Analysis of size-selected cfDNA identified clinically actionable mutations and copy number alterations that were otherwise not detected. Identification of plasma samples from patients with advanced cancer was improved by predictive models integrating fragment length and copy number analysis of cfDNA, with area under the curve (AUC) >0.99 compared to AUC <0.80 without fragmentation features. Increased identification of cfDNA from patients with glioma, renal, and pancreatic cancer was achieved with AUC > 0.91 compared to AUC < 0.5 without fragmentation features. Fragment size analysis and selective sequencing of specific fragment sizes can boost ctDNA detection and could complement or provide an alternative to deeper sequencing of cfDNA.
Errataetall: |
CommentIn: Sci Transl Med. 2018 Nov 7;10(466):. - PMID 30404860 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Science translational medicine - 10(2018), 466 vom: 07. Nov. |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
Circulating Tumor DNA |
---|
Anmerkungen: |
Date Completed 04.11.2019 Date Revised 10.02.2024 published: Print CommentIn: Sci Transl Med. 2018 Nov 7;10(466):. - PMID 30404860 Citation Status MEDLINE |
---|
doi: |
10.1126/scitranslmed.aat4921 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM290376882 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM290376882 | ||
003 | DE-627 | ||
005 | 20240210232158.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1126/scitranslmed.aat4921 |2 doi | |
028 | 5 | 2 | |a pubmed24n1286.xml |
035 | |a (DE-627)NLM290376882 | ||
035 | |a (NLM)30404863 | ||
035 | |a (PII)eaat4921 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mouliere, Florent |e verfasserin |4 aut | |
245 | 1 | 0 | |a Enhanced detection of circulating tumor DNA by fragment size analysis |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.11.2019 | ||
500 | |a Date Revised 10.02.2024 | ||
500 | |a published: Print | ||
500 | |a CommentIn: Sci Transl Med. 2018 Nov 7;10(466):. - PMID 30404860 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. | ||
520 | |a Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alterations but have rarely considered the biological properties of plasma cell-free DNA (cfDNA). We hypothesized that differences in fragment lengths of circulating DNA could be exploited to enhance sensitivity for detecting the presence of ctDNA and for noninvasive genomic analysis of cancer. We surveyed ctDNA fragment sizes in 344 plasma samples from 200 patients with cancer using low-pass whole-genome sequencing (0.4×). To establish the size distribution of mutant ctDNA, tumor-guided personalized deep sequencing was performed in 19 patients. We detected enrichment of ctDNA in fragment sizes between 90 and 150 bp and developed methods for in vitro and in silico size selection of these fragments. Selecting fragments between 90 and 150 bp improved detection of tumor DNA, with more than twofold median enrichment in >95% of cases and more than fourfold enrichment in >10% of cases. Analysis of size-selected cfDNA identified clinically actionable mutations and copy number alterations that were otherwise not detected. Identification of plasma samples from patients with advanced cancer was improved by predictive models integrating fragment length and copy number analysis of cfDNA, with area under the curve (AUC) >0.99 compared to AUC <0.80 without fragmentation features. Increased identification of cfDNA from patients with glioma, renal, and pancreatic cancer was achieved with AUC > 0.91 compared to AUC < 0.5 without fragmentation features. Fragment size analysis and selective sequencing of specific fragment sizes can boost ctDNA detection and could complement or provide an alternative to deeper sequencing of cfDNA | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Circulating Tumor DNA |2 NLM | |
700 | 1 | |a Chandrananda, Dineika |e verfasserin |4 aut | |
700 | 1 | |a Piskorz, Anna M |e verfasserin |4 aut | |
700 | 1 | |a Moore, Elizabeth K |e verfasserin |4 aut | |
700 | 1 | |a Morris, James |e verfasserin |4 aut | |
700 | 1 | |a Ahlborn, Lise Barlebo |e verfasserin |4 aut | |
700 | 1 | |a Mair, Richard |e verfasserin |4 aut | |
700 | 1 | |a Goranova, Teodora |e verfasserin |4 aut | |
700 | 1 | |a Marass, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Heider, Katrin |e verfasserin |4 aut | |
700 | 1 | |a Wan, Jonathan C M |e verfasserin |4 aut | |
700 | 1 | |a Supernat, Anna |e verfasserin |4 aut | |
700 | 1 | |a Hudecova, Irena |e verfasserin |4 aut | |
700 | 1 | |a Gounaris, Ioannis |e verfasserin |4 aut | |
700 | 1 | |a Ros, Susana |e verfasserin |4 aut | |
700 | 1 | |a Jimenez-Linan, Mercedes |e verfasserin |4 aut | |
700 | 1 | |a Garcia-Corbacho, Javier |e verfasserin |4 aut | |
700 | 1 | |a Patel, Keval |e verfasserin |4 aut | |
700 | 1 | |a Østrup, Olga |e verfasserin |4 aut | |
700 | 1 | |a Murphy, Suzanne |e verfasserin |4 aut | |
700 | 1 | |a Eldridge, Matthew D |e verfasserin |4 aut | |
700 | 1 | |a Gale, Davina |e verfasserin |4 aut | |
700 | 1 | |a Stewart, Grant D |e verfasserin |4 aut | |
700 | 1 | |a Burge, Johanna |e verfasserin |4 aut | |
700 | 1 | |a Cooper, Wendy N |e verfasserin |4 aut | |
700 | 1 | |a van der Heijden, Michiel S |e verfasserin |4 aut | |
700 | 1 | |a Massie, Charles E |e verfasserin |4 aut | |
700 | 1 | |a Watts, Colin |e verfasserin |4 aut | |
700 | 1 | |a Corrie, Pippa |e verfasserin |4 aut | |
700 | 1 | |a Pacey, Simon |e verfasserin |4 aut | |
700 | 1 | |a Brindle, Kevin M |e verfasserin |4 aut | |
700 | 1 | |a Baird, Richard D |e verfasserin |4 aut | |
700 | 1 | |a Mau-Sørensen, Morten |e verfasserin |4 aut | |
700 | 1 | |a Parkinson, Christine A |e verfasserin |4 aut | |
700 | 1 | |a Smith, Christopher G |e verfasserin |4 aut | |
700 | 1 | |a Brenton, James D |e verfasserin |4 aut | |
700 | 1 | |a Rosenfeld, Nitzan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Science translational medicine |d 2009 |g 10(2018), 466 vom: 07. Nov. |w (DE-627)NLM195151879 |x 1946-6242 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2018 |g number:466 |g day:07 |g month:11 |
856 | 4 | 0 | |u http://dx.doi.org/10.1126/scitranslmed.aat4921 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 10 |j 2018 |e 466 |b 07 |c 11 |